Cargando…

Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists

AIM: To examine whether sequential administration of (d‐Arg(35))‐sea lamprey peptide tyrosine tyrosine (1–36) (SL‐PYY) and the glucagon‐like peptide‐1 (GLP‐1) mimetic, liraglutide, has beneficial effects in diabetes. METHODS: SL‐PYY is an enzymatically stable neuropeptide Y1 receptor (NPY1R) agonist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanday, Neil, Lafferty, Ryan A., Flatt, Peter R., Irwin, Nigel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804730/ https://www.ncbi.nlm.nih.gov/pubmed/35848461 http://dx.doi.org/10.1111/dom.14821

Ejemplares similares

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
por: Tanday, Neil, et al.
Publicado: (2021)

Beneficial impact of Ac3IV, an AVP analogue acting specifically at V1a and V1b receptors, on diabetes islet morphology and transdifferentiation of alpha- and beta-cells
por: Mohan, Shruti, et al.
Publicado: (2021)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
por: Tanday, Neil, et al.
Publicado: (2021)

Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
por: Lafferty, Ryan A., et al.
Publicado: (2021)

Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review
por: Kanwar, Meeta K, et al.
Publicado: (2022)

Effects of 2 Novel PYY(1-36) Analogues, (P(3)L(31)P(34))PYY(1-36) and PYY(1-36)(Lys(12)PAL), on Pancreatic Beta-Cell Function, Growth, and Survival
por: Lafferty, Ryan A, et al.
Publicado: (2019)

Beneficial outcomes of glucagon like peptide-1 agonist therapy in a patient with Bardet Biedl syndrome and kidney transplant
por: Erturk, Banu, et al.
Publicado: (2023)

Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice
por: Lafferty, Ryan A, et al.
Publicado: (2022)

Sex-based impact of pancreatic islet stressors in Glu(CreERT2)/Rosa26-eYFP mice
por: Tanday, Neil, et al.
Publicado: (2023)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases
por: Lee, Young-Sun, et al.
Publicado: (2018)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice
por: Hasib, Annie, et al.
Publicado: (2016)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Gut Microbiota Modification via Glucagon-like Peptide-1 with Beneficial Neuroprotective Effects
por: Sayehmiri, Fatemeh, et al.
Publicado: (2022)

A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss
por: Chichura, Kylie S., et al.
Publicado: (2023)

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
por: Madsbad, Sten
Publicado: (2015)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
por: Choe, Hun Jee, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
por: Baggio, Laurie L., et al.
Publicado: (2020)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
por: Patel Chavez, Chandani, et al.
Publicado: (2021)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
por: Lisco, Giuseppe, et al.
Publicado: (2023)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
por: Geloneze, Bruno, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fe3dhn37m1f7s8hnd5ufvjie1u